Cited 41 times in
High Fluorodeoxyglucose Uptake on Positron Emission Tomography in Patients with Advanced Non–Small Cell Lung Cancer on Platinum-Based Combination Chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강원준 | - |
dc.date.accessioned | 2015-06-10T13:06:05Z | - |
dc.date.available | 2015-06-10T13:06:05Z | - |
dc.date.issued | 2006 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/111009 | - |
dc.description.abstract | PURPOSE: To evaluate response and survival for platinum-based combination chemotherapy in chemonaive patients with non-small cell lung cancer (NSCLC) according to pretreatment standardized uptake values (SUV) by fluorodeoxyglucose positron emission tomography. EXPERIMENTAL DESIGN: Patients with advanced NSCLC who had not previously received chemotherapy were eligible. Response rates and survivals were analyzed according to maximal SUVs [low (<or=7.5) versus high (>7.5), where 7.5 was the median value] before the first cycle of chemotherapy. RESULTS: Eighty-five consecutive patients were included in the retrospective study. Patients with high SUV tumors exhibited significantly higher response rates (34.1% for low SUVs versus 61.0% for high SUVs; P = 0.013). Other factors, including sex, age, histology, performance status, number of involved organs, regimens used, and disease stage, did not affect response. However, high SUVs were related with a shorter response duration (279 days for low SUVs versus 141 days for high SUVs; P = 0.003) and time to progression (282 days for low SUVs versus 169 days for high SUVs; P = 0.015). Overall survival was unaffected by maximal SUVs (623 days for low SUVs versus 464 days for high SUVs; P = 0.431). CONCLUSIONS: Patients having NSCLC with high maximal SUVs showed a better response to platinum-based combination chemotherapy but had a shorter time to progression. Tumor glucose metabolism, as determined by SUVs on fluorodeoxyglucose positron emission tomography, was found to discriminate NSCLC subsets with different clinical and biological features. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 4232~4236 | - |
dc.relation.isPartOf | CLINICAL CANCER RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/diagnosis* | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/diagnostic imaging* | - |
dc.subject.MESH | Cisplatin/administration & dosage* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorodeoxyglucose F18/pharmacokinetics* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms/diagnosis* | - |
dc.subject.MESH | Lung Neoplasms/diagnostic imaging* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Positron-Emission Tomography/methods* | - |
dc.subject.MESH | Radiopharmaceuticals* | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | High Fluorodeoxyglucose Uptake on Positron Emission Tomography in Patients with Advanced Non–Small Cell Lung Cancer on Platinum-Based Combination Chemotherapy | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Nuclear Medicine (핵의학) | - |
dc.contributor.googleauthor | Kyung-Hun Lee | - |
dc.contributor.googleauthor | Se-Hoon Lee | - |
dc.contributor.googleauthor | Dong-Wan Kim | - |
dc.contributor.googleauthor | Won Jun Kang | - |
dc.contributor.googleauthor | June-Key Chung | - |
dc.contributor.googleauthor | Seock-Ah Im | - |
dc.contributor.googleauthor | Tae-You Kim | - |
dc.contributor.googleauthor | Young Whan Kim | - |
dc.contributor.googleauthor | Yung-Jue Bang | - |
dc.contributor.googleauthor | Dae Seog Heo | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-05-2710 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00062 | - |
dc.relation.journalcode | J00564 | - |
dc.identifier.pmid | 16857796 | - |
dc.contributor.alternativeName | Kang, Won Jun | - |
dc.contributor.affiliatedAuthor | Kang, Won Jun | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 12 | - |
dc.citation.number | 14 Pt 1 | - |
dc.citation.startPage | 4232 | - |
dc.citation.endPage | 4236 | - |
dc.identifier.bibliographicCitation | CLINICAL CANCER RESEARCH, Vol.12(14 Pt 1) : 4232-4236, 2006 | - |
dc.identifier.rimsid | 51915 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.